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             Abstract 
Iclaprim is a novel diaminopyrimidine, which inhibits bacterial dihydrofolate reductase, and it is 
highly active against Gram-positive pathogens including emerging drug-resistant pathogens.  In 
vitro activity of iclaprim and comparators against 2,814 Gram-positive clinical isolates from the 
United States, Asia Pacific, Latin American and Europe collected between 2012-2014 were 
tested.  Susceptibility testing was performed according to the Clinical and Laboratory Standards 
Institute (CLSI) guidelines.  Minimum inhibitory concentration (MIC) interpretations were based 
on CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria.  
MIC50/MIC90 for all S.aureus, methicillin susceptible S. aureus, methicillin resistant S. aureus, 
beta-hemolytic streptococci, and Streptococcus pneumoniae were 0.06/0.12, 0.06/0.12, 0.06/0.5, 
0.06/0.25, and 0.06/2 µg/mL, respectively.  Iclaprim was 8 to 32-fold more potent than 
trimethoprim, the only FDA approved dihydrofolate reductase inhibitor, against all Gram-
positive isolates including resistant phenotypes.  The MIC90 of iclaprim was also lower than most 
of the comparators including linezolid and vancomycin against Gram-positive pathogens.  
Iclaprim demonstrated potent activity against a contemporary collection (2012-2014) of Gram-
positive clinical isolates from the United States, Asia Pacific, Latin America and Europe. 
 
Keywords: iclaprim, surveillance, in vitro 
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1. Introduction 
Iclaprim represents a novel diaminopyrimidine, which inhibits bacterial dihydrofolate 
reductase (DHFR) and is active against emerging drug-resistant pathogens (Sader et al., 2009; 
Schneider et al., 2003).  Trimethoprim is the only FDA approved dihydrofolate reductase 
inhibitor.  Iclaprim was designed to be more potent and to overcome trimethoprim resistance 
among Gram-positive pathogens (Oefner et al., 2009).  In addition, iclaprim does not need to be 
combined with a sulfonamide, which is commonly associated with adverse events including 
(possibly severe) allergic reactions.  Iclaprim is in Phase 3 clinical development for the treatment 
of skin and skin structure infections (SSSI).  Iclaprim exhibits potent in vitro activity against 
Gram-positive pathogens such as Staphylococcus aureus and beta-hemolytic streptococci (BHS) 
including resistant phenotypes that cause SSSI and S. aureus and S. pneumoniae that cause 
pneumonia (Sader et al., 2009; Morrissey et al., 2009).  Iclaprim demonstrates rapid in vitro 
bactericidal activity in time kill studies in human plasma (Laue et al., 2009).  In a Phase 2 
clinical trial among patients treated for skin and skin structure infections, clinical cure rates in 
the intent to treat population were 92.9% (26 of 28), 90.3% (28 of 31), and 26 of 28 (92.9%) at 
the test of cure visit in the iclaprim 0.8 mg/kg IV q12h, iclaprim 1.6 mg/kg IV q12h, and 
vancomycin 1 g IV q12h groups, respecively (Krievens et al, 2009).  In a Phase 2 clinical trial 
among patients treated for nosocomial pneumonia, clinical cure rates in the intent to treat 
population were 73.9% (17 of 23), 62.5% (15 of 24), and 52.2% (12 of 23) at the test of cure 
visit in the iclaprim 0.8 mg/mg IV q12h, iclaprim 1.2 mg/kg IV q8h, and vancomycin 1 g IV 
q12h groups, respectively (Huang et al, submitted).  Because of these findings, iclaprim is 
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potentially well suited for treating patients with SSSI and nosocomial pneumonia caused by or 
suspected Gram-positive bacteria, including multidrug resistant pathogens.  We report 
contemporary (2012-2014) surveillance data on 2,814 S. aureus, BHS, and S. pneumoniae 
isolated from patients with Gram-positive infections in the United States (US), Asia Pacific (AP), 
Latin America (LA) and Europe (EU). 
 
2. Methods 
2.1 Collection of bacterial isolates 
  Antibacterial susceptibility testing was conducted by JMI Laboratories (North Liberty, 
Iowa, USA).  A total of 2,814 nonduplicative, nonconsecutive isolates of S. aureus, BHS, and S. 
pneumoniae isolated from 2012 to 2014 were collected from multiple locations in the US, AP, 
LA and EU, including isolates from SSSI (n=776) and nosocomial pneumonia (n=860).  The 
distribution of pathogens by country are shown in Table 1.  Of the 2,814 isolates, 943 (33.5%) 
were collected from US, 981 (34.9%) EU, 432 (15.4%) AP, and 458 (16.3%) LA.   
 
2.2 Susceptibility testing  
Clinical isolates were identified by the submitting laboratories and confirmed by JMI 
Laboratories using standard bacteriologic algorithms and methodologies, including Matrix-
Assisted Laser Desorption Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS).  
When necessary, MALDI-TOF MS was performed using the Bruker Daltonics MALDI Biotyper 
(Billerica, Massachusetts, USA), following manufacturer’s instructions.  Isolates were not 
genotyped (e.g., Panton Valentine Leukocidin, alpha hemolysin, toxic shock syndrome toxin).  
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Susceptibility testing was performed by broth microdilution in accordance with the Clinical and 
Laboratory and Standards Institute (CLSI) guidelines M07-A10 (2015) and the standard 
operating procedures at JMI laboratories.  Minimum inhibitory concentration (MIC) values were 
interpreted using CLSI and European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) criteria (2015).  To date, there are no published clinical breakpoints for iclaprim. 
However, based on a number of factors (e.g., MRSA distribution of MICs, assessment of the 
pharmacokinetics/pharmacodynamics of iclaprim, and the study of the clinical outcomes of 
MRSA infections when iclaprim was used in Phase 2 and 3 studies) outlined in the CLSI M23 
guideline, an iclaprim MIC ≤1 µg/mL for S. aureus, including MRSA, has been proposed to 
FDA.  S. aureus, both methicillin-susceptible and methicillin-resistant, were tested in cation-
adjusted Mueller-Hinton broth (CA-MHB) and BHS and S. pneumoniae were tested in CA-MHB 
supplemented with 2.5-5% lysed horse blood.  Quality control and interpretation of results were 
performed in accordance with CLSI M100-S25 (2015) methods. Unlike trimethoprim (dilution 
scheme of 0.03 to 64 µg/mL), the MIC dilution scheme selected for iclaprim was 0.008 to 8 
µg/mL because concentrations >2 µg/mL are not physiologically achievable with the therapeutic 
fixed dose of iclaprim used in pivotal clinical trials.  Iclaprim and comparator antibiotic MIC 
results were within the CLSI published ranges against S. aureus ATCC 29213 and S. 
pneumoniae ATCC 49619.  Isolates were tested with MIC panels (ThermoFisher Scientific, 
Cleveland, OH, USA) of comparator antibiotics (trimethoprim, trimethoprim-sulfamethoxazole, 
ceftriaxone, erythromycin, levofloxacin, oxacillin, meropenem, tetracycline, tigecycline, 
vancomycin, linezolid, and daptomycin). 
 
3. Results 
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3.1 Iclaprim and comparator activity from 2012-2014  
The MIC50 and MIC90 for iclaprim were 0.06 µg/mL and 0.12 µg/mL, respectively, 
against key Gram-positive pathogens, including strains with resistant phenotypes, isolated from 
patients with SSSI and nosocomial pneumonia.  Table 2 shows the in vitro activity of iclaprim 
and comparators against S. aureus, MSSA, MRSA, BHS, and S. pneumoniae.  The MIC90 of 
iclaprim was lower than most of the comparators including linezolid and vancomycin, which are 
considered standard of care therapies for Gram-positive hospital infections.  Among the Gram-
positive pathogens, the MIC90 for tigecycline were lower than MIC90 for iclaprim.  For 
streptococci, the MIC90 for beta-lactams (ceftriaxone and oxacillin) were either equivalent or 
more potent than MICs for iclaprim.  Table 3 shows the cumulative percentage of isolates 
inhibited at each iclaprim MIC value. The MIC50 / MIC90 of iclaprim was identical to 
trimethoprim-sulfamethoxazole  (MIC50, 0.06 µg/mL and MIC90, 0.12 µg/mL) for all Gram-
positive pathogens.  However, trimethoprim-sulfamethoxazole had lower MIC90 values for 
MSSA and MRSA.  Based on both MIC50 and MIC90, both iclaprim and trimethoprim-
sulfamethoxazole were 8 to 32-fold more potent than trimethoprim (MIC50 and MIC90 were 1 
and 2 µg/mL, respectively), currently the only FDA approved dihydrofolate reductase inhibitor.  
For isolates with a MIC for trimethoprim of >1 µg/mL (resistance; n=366), 153 (41.9%), 15 
(4.1%), 28 (7.7%), and 168 (46.0%) isolates had a MIC for iclaprim of ≤0.25, 1, 4 and ≥8 µg/mL, 
respectively.  For isolates with a MIC for trimethoprim-sulfamethoxazole of >4 µg/mL 
(resistance; n=112), 0, 3 (2.7%), 16 (4.4%), and 91 (82.0%) isolates had a MIC for iclaprim of 
≤0.25, 1, 4 and ≥8 µg/mL, respectively.  A total of 134 (5.6%) isolates had reduced susceptibility 
to iclaprim with MICs >8 µg/mL; none of these isolates were resistant to trimethoprim.  These 
isolates were not clustered in time and/or place.  Future studies are planned to examine the 
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genotype and phenotype of these isolates. 
 
3.2 Iclaprim and comparator activity against S. aureus  
 Table 2 shows iclaprim exhibited highly potent activity against all 1,178 S. aureus 
isolates.  The MIC50 and MIC90 values were 0.06 and 0.12 µg/mL, respectively.  For 
trimethoprim, the MIC50 and MIC90 were 1 and 2 µg/mL, respectively.  For trimethoprim-
sulfamethoxazole, the MIC50 and MIC90 were 0.06 and 0.12 µg/mL, respectively.  Iclaprim was 
active against S. aureus that were resistant to erythromycin, clindamycin, levofloxacin and 
trimethoprim. 
 Iclaprim maintained activity against S. aureus regardess of methicillin susceptibility.  For 
MSSA, the MIC50 and MIC90 were 0.06 and 0.12 µg/mL, respectively.  For MRSA, the MIC50 
and MIC90 were 0.06 and 0.5 µg/mL (89.5% of isolates inhibited at MIC values 0.12 µg/mL), 
respectively.  In comparison, for MSSA, trimethoprim MIC50 and MIC90 were 1 and 2 µg/mL, 
respectively, and for MRSA, trimethoprim MIC50 and MIC90 were 2 and 8 µg/mL, respectively.  
In comparison, for MSSA, trimethoprim-sulfamethoxazole MIC50 and MIC90 were 0.06 and 0.06 
µg/mL, respectively, and for MRSA, trimethoprim-sulfamethoxazole MIC50 and MIC90 were 
0.06 and 0.25 µg/mL, respectively. 
 Iclaprim also maintained activity against S. aureus regardless of isolation from SSSI or 
nosocomial pneumonia. For SSSI, the MIC50 and MIC90 were 0.06 and 1 µg/mL, respectively.  
For nosocomial pneumonia, the MIC50 and MIC90 were 0.06 and 0.12 µg/mL, respectively (data 
not shown).  The MIC90 were higher among S. aureus associated with SSSI compared to 
nosocomial pneumonia because 14.7% (n=11) and 0% of isolates, respectively, from Brazil had a 
MIC >2 µg/mL. 
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A total of 134 (5.6%) isolates had reduced susceptibility to iclaprim with MICs >8 µg/mL 
(Table 3).  With the exception of Brazil, these isolates were not clustered in time, infection type 
and/or place.  
  
3.3 Iclaprim and comparator activity against beta-hemolytic streptococci 
The MIC50 and MIC90 for iclaprim were 0.06 and 0.25 µg/mL, respectively, against all 
199 BHS, including S. pyogenes and Streptococcus agalactiae isolates (Tables 2 and 3). In 
comparison, MIC50/MIC90 for trimethoprim and trimethoprim-sulfamethoxazole were 1 / 2 
µg/mL and 0.12/0.25 µg/mL, respectively (Table 2).  For isolates with a MIC for erythromycin 
of ≥4 µg/mL (n=60), 52 (86.7%), 2 (3.3%), and 6 (10.0%) isolates had a MIC for iclaprim of 
≤0.25, 4 and ≥8 µg/mL, respectively.   
 
3.4 Iclaprim and comparator activity against S. pneumoniae 
The MIC50 and MIC90 for iclaprim were 0.06 and 2 µg/mL, respectively, against 259 S. 
pneumoniae isolates (Tables 2 and 3).  In comparison, MIC50/MIC90 for trimethoprim and 
trimethoprim-sulfamethoxazole were 2/64 µg/mL and 0.25/8 µg/mL, respectively.  
Trimethoprim-sulfamethoxazole susceptibility was only 69.1% (CLSI criteria) against 259 
respiratory isolates of S. pneumoniae.  Iclaprim activity against these strains are shown in Table 
2.  One isolate with a MIC value of 4 µg/mL for penicillin (intermediate susceptibility) had a 
MIC value of 0.03 µg/mL for iclaprim.  Another isolate with a MIC value of >8 µg/mL for 
penicillin (resistance) had a MIC value of 1 µg/mL for iclaprim.  Iclaprim showed good activity 
against S. pneumoniae independent of the prevalence of macrolide and tetracycline resistance. 
For isolates with a MIC for erythromycin of ≥1 µg/mL (resistance; n=65), 56 (86.2%), 2 (3.1%), 
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1 (1.5%), 1 (1.5%) and 5 (7.7%) isolates had a MIC for iclaprim of ≤0.12, 1, 2, 4 and ≥8 µg/mL, 
respectively.  For isolates with a MIC for tetracycline of ≥8 µg/mL (resistance; n=49), 42 
(85.7%), 3 (6.1%), 1 (2.0%) and 3 (6.1%) isolates had a MIC for iclaprim of ≤0.25, 1, 2 and ≥8 
µg/mL, respectively. 
 
4. Discussion  
This report shows iclaprim on its own, without the synergistic combination of a 
sulfonamide, is highly active against a collection of 2,814 Gram-positive clinical isolates, 
including those with resistant phenotypes, collected between 2012-2014 from the US, AP, LA, 
and EU.  Iclaprim (MIC50, 0.06 µg/mL and MIC90, 0.12 µg/mL) was more potent than 
trimethoprim (MIC50 and MIC90 were 1 and 2 µg/mL) and identical to trimethoprim-
sulfamethoxazole (MIC50, 0.06 µg/mL and MIC90, 0.12 µg/mL).  The MIC50/MIC90 0.06/0.12 
µg/mL for S. aureus, the MIC50/MIC90 0.06/0.25 µg/mL for BHS, and the MIC50/MIC90 0.06/2 
µg/mL for S. pneumoniae documented in this analysis were consistent with those in a previous 
surveillance of 5,937 Gram-positive isolates (Sader et al., 2009). 
Resistance in S. aureus to trimethoprim is determined by a single amino acid change 
(F98Y) within the TMP-binding site of DHFR.  Iclaprim was rationally designed, using 
information from X-ray crystal data of isolated DHFR, for enhanced activity against Gram-
positive bacteria including strains with mutational changes in DHFR that determine TMP 
resistance.  Iclaprim retains sufficient binding affinity to F98Y DHFR due to additional 
hydrophobic interactions with surrounding amino acids to overcome TMP resistance (Oefner et 
al., 2009). Its activity against TMP-R clinical isolates of S. aureus and BHS has been 
demonstrated in a number of studies and is driven by the greatly increased affinity of iclaprim to 
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the DHFR target site including mutant DHFR. 
In conclusion, the results from this surveillance report confirm potent and widespread 
iclaprim susceptibility rates among contemporary (2012-2014) clinical pathogens from the US, 
AP, LA and EU.  The number of nonsusceptible isolates of S. aureus, both methicillin 
susceptible and methicillin resistant, BHS, and S. pneumoniae to iclaprim were limited.  
Continued surveillance is warranted to track the continued potentcy of iclaprim in the future and 
to detect any potential emergence of resistance. 
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Table 1  Distribution of organisms collected from the United States, Asia Pacific, Latin 
America and Europe, 2012-2014 
 
Organism US EU AP LA Total 
Staphylococcus 
aureus 
385 403 191 199 1,178 
     MRSA 192 202 90 98 582 
     MSSA 193 201 101 101 596 
BHS 75 75 23 26 199 
     S. pyogenes 37 36 12 13 98 
     S. agalactiae 38 39 11 13 101 
Streptococcus 
pneumoniae 
98 100 27 34 259 
Total 943 (33.5%) 981 (34.9%) 432 (15.4%) 458 (16.3%) 2,814 
 
Abbrevaitions: US, United States; EU, Europe; AP, Asia Pacific; LA, Latin America; MRSA, 
methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; BHS, beta-hemolytic 
streptococci
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Table 2  In vitro activity of iclaprim and comparators against isolates collected from the United States, Asia Pacific, Latin 
America and Europe, 2012-2014 
Organism Drug MIC50 MIC90 Range 
CLSI EUCAST 
%S %I %R %S %I %R 
S. aureus (n=1,178) Iclaprim 0.06 0.12 0.015-->8 - - - - - - 
 Trimethoprim 1 2 0.25-- >64 93.0 - 7.0 92.4 0.3 7.3 
 TMS 0.06 0.12 0.03 -->6 98.1 - 1.9 98.1 0.2 1.7 
 Erythromycin 0.5 >16 <0.12-->16 50.2 5.2 44.7 50.7 1.2 48.1 
 Levofloxacin 0.25 >4 <0.12-->4 59.3 59.3 0.6 40.1 59.3 40.1 
 Oxacillin 1 >2 < 0.25-->2 50.6 - 49.4 50.6 - 49.4 
 Ceftriaxone 8 >16 1—>16 50.6 - 49.4 - - - 
 Meropenem 0.12 >8 <0.06-->8 50.6 - 49.4 - - - 
 Tetracycline <0.5 8 < 0.5-->8 89.8 0.5 9.7 88.8 0.8 10.4 
 Tigecycline 0.06 0.12 < 0.015—0.5 100.0 - - 100.0 - 0.0 
 Vancomycin 1 1 0.25—2 100.0 0.0 0.0 100.0 - 0.0 
 Linezolid 1 1 < 0.12—2 100.0 - 0.0 100.0 - 0.0 
 Daptomycin 0.25 0.5 < 0.06—2 99.9 - - 99.9 0 0.1 
MRSA (n=582) Iclaprim 0.06 0.5 0.015-->8 - - - - - - 
 Trimethoprim 2 8 0.25 -->64 90.4 - 9.6 89.9 0.0 10.1 
 TMS 0.06 0.25 0.03-->8 96.9 - 3.1 96.9 0.3 2.7 
 Erythromycin >16 >16 < 0.12-->16 23.2 4.0 72.9 23.5 0.5 75.9 
 Levofloxacin >4 >4 < 0.12-->4 22.3 1.0 76.6 22.3 1.0 76.6 
 Oxacillin >2 >2 2-->2 0.0 - 100.0 0.0 - 100.0 
 Ceftriaxone >16 >16 4-->16 0.0 - 100.0 - - - 
 Meropenem 8 >8 < 0.06-->8 0.0 - 100.0 - - - 
 Tetracycline < 0.5 >8 < 0.5-->8 85.9 0.3 13.7 84.0 1.4 14.6 
 Tigecycline 0.06 0.12 < 0.015-->0.5 100.0 - - 100.0 - 0.0 
 Vancomycin 1 1 0.25—2 100.0 0.0 0.0 100.0 - 0.0 
 Linezolid 1 1 < 0.12—2 100.0 - 0.0 100.0 - 0.0 
 Daptomycin 0.25 0.5 < 0.06--1 100.0 - - - - 0.0 
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MSSA (n=596) Iclaprim 0.06 0.12 0.015-->8 - - - - - - 
 Trimethoprim 1 2 0.25
__
>64 95.5 - 4.5 95.0 0.5 4.5 
 TMS 0.06 0.06 0.03
__
>8 99.3 - 0.7 99.3 0.0 0.7 
 Erythromycin 0.25 >16 <0.12--->16 76.5 6.4 17.1 77.2 1.8 21.0 
 Levofloxacin 0.25 0.25 <0.12-->4 95.5 0.2 4.4 95.5 0.2 4.4 
 Oxacillin 0.5 0.5 <0.25--1 100.0 - 0.0 100.0 - 0.0 
 Ceftriaxone 4 4 1
__
>16 100.0 - 0.0 - - - 
 Meropenem <0.06 0.12 <0.06--2 100.0 - 0.0 - - - 
 Tetracycline <0.05 <0.5 <0.5-->8 93.6 0.7 5.7 93.5 0.2 6.4 
 Tigecycline 0.06 0.06 <0.015--0.5 100.0 - - 100.0 - 0.0 
 Vancomycin 1 1 0.5--2 100.0 0.0 0.0 100.0 - 0.0 
 Linezolid 1 1 0.25--2 100.0 - 0.0 100.0 - 0.0 
 Daptomycin 0.25 0.5 0.12
--
02 99.8 - - 99.8 - 0.2 
BHS (n=199) Iclaprim 0.06 0.25 0.008-- >8 - - - - - - 
 Trimethoprim 1 2 0.12 --- >64 - - - 93.0 - 7 
 TMS 0.12 0.25 0.03-- >8 - - - 98.0 1.5 0.5 
 Erythromycin ≤0.12 >16 ≤0.12—16 72.9 1.5 25.6 72.9 1.5 25.6 
 Levofloxacin 0.5 1 ≤0.12-- >4 99.0 0.0 1.0 94.0 5.0 1.0 
 Oxacillin ≤0.06 ≤0.06 ≤0.06 – >2 100.0 - - 100.0 - 0.0 
 Ceftriaxone 0.06 0.12 ≤ 0.015 –>16 99.5 - - 100.0 - 0 
 Meropenem ≤0.06 ≤0.06 ≤0.015 –32 100.0 - - 100.0 - 0.0 
 Tetracycline >8 >8 ≤0.5 -- >8 43.7 0.5 55.8 42.7 1.0 56.3 
 Tigecycline 0.03 0.03 ≤0.015—0.06 100.0 - - 100.0 0.0 0.0 
 Vancomycin 0.25 0.5 0.25-1 100.0 - - 100.0 - 0.0 
 Linezolid 1 1 0.5 –1 100.0 - - 100.0 0.0 0.0 
 Daptomycin 0.12 0.25 ≤0.06 – 0.5 100.0 - - 100.0 - 0.0 
S. pyogenes (N=98) Iclaprim 0.06 0.25 0.008-- >8 - - - - - - 
 Trimethoprim 1 2 0.12 --- >64 - - - 93.0 - 7 
 TMS 0.12 0.25 0.03-- >8 - - - 98.0 1.5 0.5 
 Erythromycin ≤0.12 >16 ≤0.12—16 72.9 1.5 25.6 72.9 1.5 25.6 
 Levofloxacin 0.5 1 ≤0.12-- >4 99.0 0.0 1.0 94.0 5.0 1.0 
 Oxacillin ≤0.06 ≤0.06 ≤0.06 – >2 100.0 - - 100.0 - 0.0 
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 Ceftriaxone 0.06 0.12 ≤ 0.015 –>16 99.5 - - 100.0 - 0 
 Meropenem ≤0.06 ≤0.06 ≤0.06 –32 100.0 - - 100.0 - 0.0 
 Tetracycline >8 >8 ≤0.5 -- >8 43.7 0.5 55.8 42.7 1.0 56.3 
 Tigecycline 0.03 0.03 ≤0.015—0.06 100.0 - - 100.0 0.0 0.0 
 Vancomycin 0.25 0.5 0.25-1 100.0 - - 100.0 - 0.0 
 Linezolid 1 1 0.5 –1 100.0 - - 100.0 0.0 0.0 
 Daptomycin 0.12 0.25 ≤0.06 – 0.5 100.0 - - 100.0 - 0.0 
S. agalactiae (N=101) Iclaprim 0.06 0.25 0.008-- >8 - - - - - - 
 Trimethoprim 1 2 0.12 --- >64 - - - 93.0 - 7 
 TMS 0.12 0.25 0.03-- >8 - - - 98.0 1.5 0.5 
 Erythromycin ≤0.12 >16 ≤0.12—16 72.9 1.5 25.6 72.9 1.5 25.6 
 Levofloxacin 0.5 1 ≤0.12-- >4 99.0 0.0 1.0 94.0 5.0 1.0 
 Oxacillin ≤0.06 ≤0.06 ≤0.06 – >2 100.0 - - 100.0 - 0.0 
 Ceftriaxone 0.06 0.12 ≤ 0.015 –>16 99.5 - - 100.0 - 0 
 Meropenem ≤0.06 ≤0.06 ≤0.015 –32 100.0 - - 100.0 - 0.0 
 Tetracycline >8 >8 ≤0.5 -- >8 43.7 0.5 55.8 42.7 1.0 56.3 
 Tigecycline 0.03 0.03 ≤0.015—0.06 100.0 - - 100.0 0.0 0.0 
 Vancomycin 0.25 0.5 0.25-1 100.0 - - 100.0 - 0.0 
 Linezolid 1 1 0.5 –1 100.0 - - 100.0 0.0 0.0 
 Daptomycin 0.12 0.25 ≤0.06 – 0.5 100.0 - - 100.0 - 0.0 
S. pneumoniae 
(n=259) 
Iclaprim 0.06 2 0.015-->8 - - - - - - 
 Trimethoprim 2 64 0.25-- >64 - - - - - - 
 TMS 0.25 8 0.12-- >8 69.1 12.0 18.9 78.0 3.1 18.9 
 Erythromycin ≤0.12 >16 ≤0.12-- >16 58.7 0.8 40.5 58.7 0.8 40.5 
 Levofloxacin 1 1 0.5-- >4 97.7 0.4 1.9 97.7 - 2.3 
 Penicillin ≤0.06 2 ≤0.06-->8 55.2 24.7 20.1 55.2 - 44.8 
 Ceftriaxone 0.03 1 ≤0.015—16 75.3 15.8 8.9 75.3 24.3 0.4 
 Meropenem ≤0.06 0.5 ≤0.06—2 76.4 18.9 4.6 76.4 22.8 0.8 
 Tetracycline ≤0.5 >8 ≤0.5—0.8 67.6 0.4 32.0 67.6 0.4 32.0 
 Tigecycline 0.03 0.03 ≤0.015—0 99.6 - . - - - 
 Vancomycin 0.25 0.5 ≤0.12—0.5 100.0 - - 100.0 - 0.0 
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 Linezolid 1 1 ≤0.12--2 100.0 - - 100.0 0.0 0.0 
 Daptomycin 0.12 0.25 ≤0.06—0.5 - - - - - - 
Abbreviations: MIC, minimal inhibitory concentration; CLSI, Clinical and Laboratory Standards Institute; EUCAST, European 
Committee on Antimicrobial Susceptibility Testing; S, susceptible; I, intermediate; R, resistant; TMS,  trimethoprim-sulfamethoxazole; 
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; BHS, beta-hemolytic streptococci 
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Table 3 Cumulative inhibition by iclaprim, trimethorprim and trimethoprim-sulfamethoxazole at MIC values by pathogen group, 
2012-2014 
Organism Drug Number (cumulative percentage) inhibited by drug MIC (µg/mL) 
≤0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 >* 
S. aureus 
(n=1,178) 
Iclaprim 143 
(12.5) 
746 
(75.5) 
196 
(92.1) 
7 
(92.7) 
1 
(92.8) 
6 
(93.3) 
0 
(93.3) 
4 
(93.6) 
8 
(94.3) 
-- -- -- 
67 
(100) 
 Trimethoprim 
-- -- -- 
18 
(1.5) 
268 
(24.3) 
707 
(84.3) 
96 
(92.4) 
3 
(92.7) 
3 
(93.2) 
3 
(93.2) 
4 
(93.5) 
6 
(94.1) 
70 
(100.0) 
 TMS 55 
(4.7) 
963 
(86.4) 
67 
(92.1) 
26 
(94.3) 
19 
(95.9) 
18 
(97.5) 
8 
(98.1) 
2 
(98.3) 
5 
(98.7) 
-- -- -- 
15 
(100.0) 
MSSA 
(n=596) 
Iclaprim 67 
(11.7) 
370 
(73.3) 
127 
(94.6) 
5 
(95.5) 
0 
(95.5) 
0 
(95.5) 
0 
(95.5) 
1 
(95.6) 
0 
(95.6) 
-- -- -- 26 
(100.0) 
 Trimethoprim -- -- -- 8 
(1.3) 
120 
(21.5) 
376 
(84.6) 
62 
(95.0) 
3 
(95.5) 
0 
(95.5) 
0 
(95.5) 
1 
(95.6) 
0 
(95.6) 
26 
(100.0) 
 TMS 23 
(3.9) 
529 
(92.6) 
18 
(95.6) 
4 
(96.3) 
8 
(97.70) 
7 
(98.8) 
3 
(99.3) 
0 
(99.3) 
1 
(99.5) 
-- -- -- 3 
(100.0) 
MRSA 
(n=582) 
Iclaprim 76 
(13.4) 
376 
(77.7) 
69 
(89.5) 
2 
(89.9) 
1 
(90.0) 
6 
(91.1) 
0 
(91.1) 
3 
(91.6) 
8 
(93.0) 
-- -- -- 41 
(100.0) 
 Trimethoprim -- -- -- -- 10 
(1.7) 
148 
(27.1) 
331 
(84.0) 
34 
(89.9) 
3 
(90.4) 
3 
(90.9) 
3 
(91.4) 
6 
(92.4) 
44 
(100.0) 
 TMS 32 
(5.5) 
434 
(80.1) 
49 
(88.5) 
22 
(92.3) 
11 
(94.2) 
11 
(96.0) 
5 
(96.9) 
2 
(97.3) 
4 
(97.9) 
-- -- -- 12 
(100.0) 
BHS 
(n=199) 
Iclaprim 84 
(42.2) 
20 
(52.3) 
53 
(78.9) 
32 
(95.0) 
4 
(97.0) 
1 
(97.5) 
0 
(97.5) 
0 
(97.5) 
0 
(97.5) 
-- -- -- 5 
(100.0) 
 Trimethoprim -- -- 11 
(5.5) 
48 
(29.6) 
32 
(45.7) 
51 
(71.4) 
43 
(93.0) 
8 
(97.0) 
0 
(97.5) 
1 
(97.5) 
0 
(97.5) 
0 
(97.5) 
5 
(100.0) 
 TMS 2 
(1.0) 
61 
(31.7) 
111 
(87.4) 
19 
(97.0) 
1 
(97.5) 
 1 
(98.0) 
3 
(99.5) 
0 
(99.5) 
0 
(99.5) 
-- -- -- 1 
(100.0) 
S. pyogenes 
(N=98) 
Iclaprim 42 
(42.9) 
11 
(54.1) 
24 
(78.6) 
15 
(93.9) 
2 
(95.9) 
1 
(96.9) 
0 
(96.9) 
0 
(96.9) 
0 
(96.9) 
-- -- -- 3 
(100.0) 
 Trimethoprim -- -- 6 
(6.1) 
23 
(29.6) 
16 
(45.9) 
26 
(72.4) 
21 
(93.9) 
3 
(96.9) 
0 
(96.9) 
0 
(96.9) 
0 
(96.9) 
0 
(96.9) 
3 
(100.0) 
 TMS 1 31 52 9 1 1 2 0 0 -- -- -- 1 
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(1.0) (32.7) (85.7) (94.9) (95.9) (96.9) (99.0) (99.0) (99.0) (100.0) 
S. 
agalactiae 
(N=101) 
Iclaprim 42 
(41.6) 
9 
(50.5) 
29 
(79.2) 
17 
(96.0) 
2 
(98.0) 
0 
(98.0) 
0 
(98.0) 
0 
(98.0) 
0 
(98.0) 
-- -- --     2 
(100.0) 
  Trimethoprim -- -- 5 
(5.0) 
25 
(29.7) 
16 
(45.5) 
25 
(70.3) 
22 
(92.1) 
5 
(97.0) 
0 
(97.0) 
1 
(98.0) 
0 
(98.0) 
0 
(98.0) 
2 
(100.0) 
 TMS 1 
(1.0) 
30 
(30.7) 
57 
(87.1)  
12 
(99.0) 
0 
(99.0) 
0 
(99.0) 
1 
(99.0) 
0 
(99.0) 
0 
(99.0) 
-- -- -- 0 
(100.0) 
S. 
pneumoniae 
(n=259) 
Iclaprim 73 
(28.2) 
109 
(70.3) 
23 
(79.2) 
0 
(79.2) 
3 
(80.3) 
8 
(83.4) 
24 
(92.7) 
3 
(93.8) 
12 
(98.5) 
-- -- -- 4 
(100.0) 
 Trimethoprim -- -- -- 1 
(0.4) 
6 (2.7) 54 
(23.6) 
123 
(71.0) 
21 
(79.2) 
1 
(79.5) 
1 
(79.9) 
7 
(82.6) 
28 
(93.4) 
17 
(100.0) 
 TMS -- -- 17 
(6.2) 
143 
(61.4) 
20 
(69.1) 
23 
(78.0) 
8 
(81.1) 
7 
(83.8) 
36 
(97.7) 
-- -- -- 6 
(100.0) 
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*Greater than the highest MIC dilution tested 
Abbreviations: TMS,  trimethoprim-sulfamethoxazole; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. 
aureus; BHS, beta-hemolytic streptococci
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Highlights 
 Iclaprim is active in vitro against Gram-positive pathogens.   
 Iclaprim was 8 to 32-fold more potent than trimethoprim.   
 The MIC90 of iclaprim was also lower than most of the antibiotics tested. 
 Iclaprim may be a treatment for skin and skin structure and pneumonia infections. 
